Study guide

13.1 Local Anesthetics & Vasoconstrictors

NDEB Assessment of Fundamental Knowledge AFK

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the AFK & NDEB Equivalency Process 1.2 Format, Scoring, Attempts & Exam-Day Rules 1.3 Official Blueprint Weights & Study Strategy

2 Chapter 1: Head & Neck Anatomy

1.1 Osteology, Fascial Spaces & Odontogenic Spread 1.2 Cranial Nerves Relevant to Dentistry 1.3 Vascular Supply, Lymphatics, TMJ & Mastication

3 Chapter 2: Human Physiology for Dentistry

2.1 Cardiovascular & Respiratory Physiology 2.2 Renal, Endocrine & Acid-Base Physiology 2.3 Neuromuscular Physiology & Salivary Function

4 Chapter 3: Biochemistry, Nutrition & Biomaterials

3.1 Metabolism, Enzymes & Oral Biochemistry 3.2 Vitamins, Minerals & Nutritional Deficiencies 3.3 Biomaterials Science: Properties & Biocompatibility

5 Chapter 4: Oral Histology, Embryology & Growth

4.1 Tooth Development & Oral Embryology 4.2 Enamel, Dentin, Cementum, Pulp & Periodontium Histology 4.3 Craniofacial Growth & Development

6 Chapter 5: Microbiology, Immunology & Cariology

5.1 Oral Microbiome, Pathogens & Biofilms 5.2 Immunology & Hypersensitivity in the Oral Cavity 5.3 Cariology: Etiology, Progression & Prevention Science

7 Chapter 6: Dental Anatomy & Occlusion

6.1 Permanent & Primary Tooth Morphology & Roots 6.2 Eruption Sequences & FDI Numbering 6.3 Occlusion Principles & Angle Classification

8 Chapter 7: Restorative Principles & Direct Materials

7.1 Caries Diagnosis & Operative Principles 7.2 Amalgam, Composite Resin & Glass Ionomer 7.3 Adhesion, Bonding & Pulp Protection

9 Chapter 8: Indirect Restorations & Prosthodontics

8.1 Crowns, Bridges, Onlays & Preparation Design 8.2 Complete Dentures & Removable Partial Dentures 8.3 Occlusion Concepts in Prosthodontics

10 Chapter 9: Implants & Advanced Restorative

9.1 Implant Biology & Osseointegration 9.2 Implant Planning, Prosthetics & Complications 9.3 Clinical Dental Materials Selection & Failures

11 Chapter 10: Oral Medicine — Mucosal Disease

10.1 White, Red & Ulcerative Mucosal Lesions 10.2 Oral Cancer & Premalignant Conditions 10.3 Vesiculobullous & Immune-Mediated Mucosal Disease

12 Chapter 11: Oral Pathology — Hard Tissues

11.1 Cysts of the Jaws 11.2 Odontogenic Tumors 11.3 Bone Pathology & Fibro-Osseous Lesions

13 Chapter 12: Salivary Disease, Systemic Manifestations & Oral Radiology

12.1 Salivary Gland Disease 12.2 Systemic Disease Oral Manifestations 12.3 Radiation Physics & Radiographic Technique 12.4 Radiographic Anatomy, Lesions & Interpretation

14 Chapter 13: Local Anesthesia & Analgesia

13.1 Local Anesthetics & Vasoconstrictors 13.2 Injection Techniques, Failures & Complications 13.3 Analgesics, Anxiolysis & Sedation

15 Chapter 14: Systemic Pharmacology & Medical Emergencies

14.1 Antibiotics & Antimicrobials in Dentistry 14.2 Drug Interactions & the Medically Compromised Patient 14.3 Recognition of Medical Emergencies in the Dental Office 14.4 Emergency Drugs & Management Protocols

16 Chapter 15: Periodontics Foundations

15.1 Periodontal Anatomy & Pathogenesis 15.2 2017 AAP Classification of Periodontal Diseases 15.3 Periodontal Examination & Diagnosis

17 Chapter 16: Periodontal Therapy & Systemic Links

16.1 Nonsurgical Periodontal Therapy 16.2 Surgical Periodontics Basics 16.3 Periodontal–Systemic Relationships

18 Chapter 17: Endodontics

17.1 Pulp Biology & Endodontic Diagnosis 17.2 Canal Morphology & Access Preparation 17.3 Instrumentation, Irrigation & Obturation 17.4 Endodontic Emergencies, Trauma & Retreatment

19 Chapter 18: Oral Surgery, Trauma & Orofacial Pain

18.1 Exodontia Principles & Complications 18.2 Impacted Teeth & Minor Oral Surgery 18.3 Maxillofacial Trauma 18.4 Orofacial Pain, TMD & Dental Emergencies

20 Chapter 19: Orthodontics

19.1 Growth, Development & Orthodontic Diagnosis 19.2 Malocclusion Classification & Treatment Planning 19.3 Appliances, Interceptive & Comprehensive Orthodontics

21 Chapter 20: Pediatric Dentistry

20.1 Behavior Management & Primary Dentition Care 20.2 Pediatric Pulp Therapy 20.3 Pediatric Trauma & Space Management

22 Chapter 21: Geriatric & Special Needs Dentistry

21.1 Geriatric Dentistry Considerations 21.2 Special Needs Patients in Dental Practice

23 Chapter 22: Prevention & Evidence-Based Dentistry

22.1 Fluoride, Sealants & Prevention Strategies 22.2 Epidemiology, Caries Indices & Public Health 22.3 Evidence-Based Dentistry & Biostatistics

24 Chapter 23: Infection Control, Ethics & Jurisprudence

23.1 Infection Control & Sterilization 23.2 Ethics & Professionalism for Canadian Practice 23.3 Jurisprudence, Consent & Clinical Records

25 Chapter 24: Integrated Review & Exam Strategy

24.1 High-Yield Differentials Across Domains 24.2 Case Vignette Reasoning Patterns 24.3 Exam-Day Strategy & Pathway Next Steps (ACJ/NDECC)

13.1 Local Anesthetics & Vasoconstrictors

Key Takeaways Explain This Topic AI

Amide LAs (lidocaine, articaine, mepivacaine, bupivacaine, prilocaine) undergo primarily hepatic metabolism; esters (benzocaine, procaine) are hydrolyzed by plasma cholinesterases and historically show more allergic potential.

Onset relates to pKa and tissue pH (non-ionized base crosses nerve membrane); duration tracks protein binding, lipid solubility, and vasoconstrictors—inflamed acidic tissue impairs infiltration anesthesia.

Know cartridge math (2% ≈ 36 mg/1.8 mL; 4% ≈ 72 mg) and teaching MRDs: lidocaine/articaine ~7 mg/kg with vaso, mepivacaine ~4.4–6.6 mg/kg, bupivacaine ~1.3–2 mg/kg, with absolute caps.

Epinephrine 1:100,000 delivers ~18 μg/cartridge vs ~9 μg at 1:200,000; limit or avoid exogenous epi in unstable cardiovascular disease, uncontrolled hyperthyroidism, cocaine intoxication, and relevant drug interactions.

Methemoglobinemia is classically linked to prilocaine and benzocaine—cyanosis with chocolate-brown blood; treat supportively and with methylene blue when indicated.

Last updated: July 2026

13.1 Local Anesthetics & Vasoconstrictors

Quick Answer: Dental local anesthetics (LAs) are mostly amides (hepatic metabolism) rather than esters (plasma esterases; more allergy). Onset tracks pKa and tissue pH (lower pKa / more non-ionized base → faster entry). Duration tracks protein binding and lipid solubility , amplified by vasoconstrictors . Know cartridge math, maximum recommended doses (lidocaine, articaine, mepivacaine, bupivacaine, prilocaine), epinephrine 1:100,000 vs 1:200,000 , absolute/relative epi contraindications , and methemoglobinemia risk with prilocaine/benzocaine .

Pharmacology is a major AFK slice ( ~14% of the blueprint when grouped with systemic drugs and emergencies). Local anesthesia items test mechanism, drug selection, dose safety, vasoconstrictor decisions in medically compromised patients, and recognition of toxicity/methemoglobinemia—not memorization of obscure brand names alone.

Mechanism of Action

Local anesthetics block voltage-gated sodium channels on nerve axons from the inside of the membrane (use-dependent block). The non-ionized (free base) form crosses the lipid nerve membrane; inside the axoplasm the ionized (cationic) form binds the channel and prevents Na⁺ influx → no depolarization → no propagation of pain, temperature, and other sensory (and, at high concentration, motor) impulses.

Clinical implications of the mechanism:

Concept Chairside meaning

Inflamed/acidic tissue More drug ionized outside the nerve → poor penetration → “hot tooth” failures with infiltration

  • pKa Fraction non-ionized at physiologic pH; lower pKa generally faster onset
  • Lipid solubility Potency and often longer duration (nerve membrane partitioning)
  • Protein binding Correlates with duration of action
  • Vasodilation Most LAs dilate vessels → ↑ systemic absorption → shorter block unless vasoconstrictor added

Nerve fiber susceptibility (teaching order, not absolute): small myelinated fibers and unmyelinated C fibers for pain/temperature are more readily blocked than large motor fibers—patients may still feel pressure/vibration while pain is abolished.

Amides vs Esters

Feature Amides Esters

Common dental examples Lidocaine, articaine*, mepivacaine, bupivacaine, prilocaine Procaine, tetracaine, benzocaine (topical), cocaine (historical)

Metabolism Primarily hepatic microsomal enzymes Plasma pseudocholinesterase (and tissue esterases)

Allergy potential True IgE allergy rare ; reactions often to preservatives/vasoconstrictor Higher historic allergy rate (PABA metabolites)

  • Cross-reactivity Within amide class uncommon but possible Cross-reactivity among esters more likely
  • AFK default Nearly all injectable dental LAs Mostly topicals (benzocaine) in modern practice

*Articaine is an amide with an additional thiophene ring and an ester side chain hydrolyzed in plasma—short plasma half-life, but classified and used as an amide injectable.

Allergy teaching points:

Documented true LA allergy is uncommon; many “allergies” are syncope, epinephrine effects, or toxicity .

If a true amide allergy is proven, consider ester alternatives or allergy/anesthesia referral—do not casually switch without history.

Methylparaben (multi-dose vials) and sulfites (with epinephrine) can cause reactions mistaken for LA allergy.

Sodium bisulfite/metabisulfite antioxidant accompanies epinephrine—relevant in sulfite-sensitive asthmatics.

pKa, Onset, Duration, and Potency

Property Effect on clinical block High-yield examples

pKa close to tissue pH (more free base) Faster onset Mepivacaine pKa ~7.6; lidocaine ~7.7; bupivacaine ~8.1 (slower onset)

  • High lipid solubility Greater potency; often longer block Bupivacaine highly lipid soluble
  • High protein binding Longer duration Bupivacaine ~95% protein bound
  • Intrinsic vasodilation Shorter plain duration Lidocaine dilates; mepivacaine less so (usable plain)
  • Tissue inflammation (↓ pH) Delayed/failed onset Infected molar infiltration failures

Mnemonic structure for AFK recall:

  • Onset ≈ pKa + tissue pH + proximity to nerve
  • Duration ≈ protein binding + lipid solubility + vasoconstrictor + vascularity of site
  • Potency ≈ lipid solubility

Buffered LA (alkalinization) increases free base fraction and may speed onset and reduce injection pain—conceptually tested more than brand protocols.

Core Injectable Agents and Maximum Doses

Doses below are widely taught dental maximum recommended doses (MRDs) . Always use the lower of weight-based or absolute maximum , reduce for children/frail/elderly/hepatic disease, and count all cartridges of all agents. Canadian and US teaching numbers are close; know the table and the arithmetic.

Agent Typical dental concentration Approx. MRD (teaching) Notes

Lidocaine 2% ± epi 1:100k or 1:50k 7 mg/kg with epi (absolute often 500 mg ); ~4.4 mg/kg plain Gold-standard amide; intermediate duration with epi

Articaine 4% ± epi 1:100k or 1:200k 7 mg/kg (absolute often 500 mg ) Excellent bone diffusion; infiltration often effective in mandible; rare paresthesia association debated with 4% solutions

Mepivacaine 3% plain or 2% with levonordefrin 1:20k ~4.4 mg/kg plain; ~6.6 mg/kg with vaso Prefer when epinephrine should be minimized; shorter plain duration

Bupivacaine 0.5% ± epi ~1.3–2 mg/kg (absolute often 90 mg ) Long duration; post-op pain control; higher cardiotoxicity risk

Prilocaine 4% ± vaso (felypressin in some markets) ~6–8 mg/kg (absolute often 400–600 mg by source) Methemoglobinemia risk at high dose

Cartridge arithmetic (must be automatic)

Standard dental cartridge ≈ 1.8 mL (some systems 1.7–2.2 mL—read label).

1% solution = 10 mg/mL .

Therefore 2% lidocaine = 20 mg/mL × 1.8 mL ≈ 36 mg LA per cartridge .

4% articaine = 40 mg/mL × 1.8 mL ≈ 72 mg LA per cartridge .

0.5% bupivacaine = 5 mg/mL × 1.8 mL ≈ 9 mg LA per cartridge .

Worked example: 70 kg adult, lidocaine 2% with epi, MRD 7 mg/kg → 490 mg (cap 500) → 490/36 ≈ 13 cartridges theoretical maximum— never approach this clinically ; use the fewest cartridges for profound anesthesia and factor other agents already given.

Pediatric trap: weight-based MRD falls fast; 20 kg child at 7 mg/kg lidocaine with epi = 140 mg ≈ 3–4 cartridges —easy to exceed if multiple quadrants are treated carelessly.

Vasoconstrictors: Epinephrine Concentrations

Vasoconstrictors slow systemic absorption , deepen and prolong anesthesia, reduce bleeding in the field, and allow higher effective LA doses within safety limits by lowering peak plasma levels.

Epinephrine math

  • Concentration Epinephrine per mL In 1.8 mL cartridge
  • 1:50,000 0.02 mg/mL (20 μg/mL) 0.036 mg (36 μg)
  • 1:100,000 0.01 mg/mL (10 μg/mL) 0.018 mg (18 μg)
  • 1:200,000 0.005 mg/mL (5 μg/mL) 0.009 mg (9 μg)

1:100,000 vs 1:200,000:

  • Issue 1:100,000 1:200,000
  • Soft-tissue/pulpal duration Slightly longer / denser for some procedures Adequate for most restorative work
  • Hemostasis Better local hemostasis Less vasoconstriction
  • Systemic epi load Higher per cartridge Lower—prefer when CV risk moderate
  • AFK decision rule Surgical hemostasis needs Routine restorative with medical caution

Levonordefrin (often 1:20,000 with mepivacaine) is primarily α-agonist with less β activity than epinephrine—still not “free” of cardiovascular effects.

Maximum epinephrine teaching ceilings (healthy vs cardiac risk) vary by guideline era; classic dental teaching often cites ~ 0.2 mg epi total in healthy adults and ~0.04 mg in significant cardiovascular disease (roughly 2 cartridges of 1:100,000). Use lowest effective concentration/dose, aspirate, inject slowly, and monitor.

Contraindications and Cautions for Epinephrine

Category Examples / rationale

Absolute / near-absolute Uncontrolled hyperthyroidism; pheochromocytoma; cocaine or amphetamine intoxication (arrhythmia risk); sulfite allergy when only sulfite-containing epi solutions available

Significant cardiovascular disease Unstable angina, recent MI, severe uncontrolled hypertension, refractory arrhythmias—limit or avoid; medical consultation; prefer plain mepivacaine when profound short block suffices

Drug interactions Non-selective β-blockers (unopposed α → hypertensive response risk); TCAs (potentiate pressors—limit epi); MAOIs historically listed; digoxin/arrhythmia risk with excess catecholamines

Hyperthyroidism (controlled vs not) Controlled often OK with limited epi; uncontrolled—avoid

Pregnancy Lidocaine with limited epi is widely used when indicated (FDA legacy category B teaching for lidocaine); avoid unnecessary high dose; consult current guidance

Glaucoma (narrow-angle) Systemic catecholamines caution in older texts—usually not a ban on dental cartridges at standard doses but know the flag

Endogenous catecholamines from pain and anxiety often exceed the small epi dose in one carefully given cartridge— profound anesthesia itself is cardioprotective by reducing stress response. Do not withhold needed LA out of unfounded fear; withhold or limit epi when disease/drugs make exogenous catecholamines dangerous.

Methemoglobinemia

Methemoglobin (MetHb) is hemoglobin iron in the Fe³⁺ state that cannot carry oxygen well; patients appear cyanotic with chocolate-brown blood and may have low SpO₂ that responds poorly to oxygen alone until MetHb is reduced.

Feature Detail

Dental culprits Prilocaine (metabolite o-toluidine), benzocaine topical (especially sprays), rarely articaine or others

Risk factors High dose, infants/young children, G6PD deficiency, congenital methemoglobinemia, concurrent oxidant drugs

Clinical Cyanosis, headache, fatigue, dyspnea, tachycardia; severe → lethargy, coma, death

Clue Cyanosis with relatively normal PaO₂ on ABG; pulse oximetry often ~85% plateau; co-oximetry diagnoses MetHb %

Treatment Stop offending agent; supportive O₂; methylene blue IV (first-line in symptomatic significant MetHb; caution in G6PD deficiency); ICU/emergency transfer

AFK stem pattern: child after multiple benzocaine applications or adult after high-dose prilocaine develops cyanosis → think methemoglobinemia, not simple hypoxia from airway obstruction alone (though both need ABC assessment).

Choosing Agents—Integrated Clinical Rules

Healthy adult restorative, short–moderate duration: lidocaine 2% with epi 1:100k or articaine 4% with epi 1:200k/1:100k per preference and site.

Need long post-op soft-tissue anesthesia (e.g., surgery): bupivacaine 0.5% with epi for prolonged analgesia—warn about soft-tissue injury (lip/tongue biting), especially in children.

Epinephrine minimization: mepivacaine 3% plain for short procedures; limit total dose carefully.

Infected “hot” tooth: block away from infection (nerve block) rather than infiltration into abscess; consider supplemental techniques (next section).

Hepatic failure: amides accumulate—reduce dose, simplify regimen, consider medical consult; esters theoretically extrahepatic but rarely used as injectables.

Pseudocholinesterase deficiency: prolongs ester metabolism—avoid high-dose esters.

Always aspirate, inject slowly, stay below MRD, document cartridges.

  • Rapid review list
  • Amides = liver; esters = plasma; benzocaine topical ester
  • Free base crosses membrane; acid tissue → failure
  • pKa ↓ → onset ↑; protein binding ↑ → duration ↑
  • 2% × 1.8 mL ≈ 36 mg; 4% ≈ 72 mg per cartridge
  • Lidocaine/articaine ~7 mg/kg with vaso; bupivacaine ~1.3–2 mg/kg
  • 1:100k = 18 μg epi/cartridge; 1:200k = 9 μg
  • Limit epi in unstable CV disease, uncontrolled hyperthyroid, cocaine
  • Prilocaine/benzocaine → methemoglobinemia; methylene blue

Section 13.2 applies these drugs to injection anatomy, failures, and complications including systemic toxicity stages.